MacroGenics

MGNX

Market cap $100M

Overview Fund Activity

1.59 USD

-0.06

3.64%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.58

-0.01

0.63%

1 day

-3.64%

5 days

-19.29%

1 month

8.16%

3 months

2.58%

6 months

-33.19%

Year to date

-51.82%

1 year

-55.96%

5 years

-94.53%

10 years

-94.06%

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Employees: 341

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

66% more call options, than puts

Call options by funds: $83K | Put options by funds: $50K

8.77% less ownership

Funds ownership: 85.26% [Q1] → 76.49% (-8.77%) [Q2]

12% less funds holding

Funds holding: 127 [Q1] → 112 (-15) [Q2]

14% less capital invested

Capital invested by funds: $68.3M [Q1] → $58.4M (-$9.84M) [Q2]

24% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 34

37% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 41

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

214% upside

Avg. target

$5

214% upside

High target

$5

214% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Leerink Partners

$5

Outperform

Maintained

15 Aug 2025

See Analyst Rankings

Financial journalist opinion

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics' President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY.

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Zacks Investment Research

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.89 per share a year ago.

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as President and Chief Executive Officer for the past 24 years.

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

MacroGenics: Working On That Road To Recovery

I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with key phase 2 data expected in late 2025, and additional programs like MGC-026 and MGC-028 progressing. The recent royalty deal extends the cash runway, but liquidity concerns remain, and further asset sales or dilution may be necessary.

MacroGenics: Working On That Road To Recovery

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard in exchange for a capped royalty interest on future global net sales of ZYNYZ (retifanlimab-dlwr). ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Zacks Investment Research

4 Medical Product Stocks to Watch From a Challenging Industry

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

4 Medical Product Stocks to Watch From a Challenging Industry

Zacks Investment Research

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago.

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025.

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™